Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995
- PMID: 10940145
- PMCID: PMC1495583
- DOI: 10.1046/j.1525-1497.2000.03499.x
Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995
Abstract
Objective: To determine the prevalence and duration of postmenopausal hormone replacement therapy (HRT) use and identify correlates of adherence to therapy.
Design: Population-based cohort study.
Setting: Staff-model health maintenance organization.
Participants: Female members, 40 years and older.
Measurements and main results: Prevalence and duration of use were measured between 1990 and 1995. Duration was assessed by Kaplan-Meier and proportional hazards methods. Hormone replacement therapy use increased from 10.3% in 1990 to 20.7% in 1995. Greatest use (24%) occurred among menopausal women age 50 to 54 years. Less than 5% of women 75 and older used HRT. Among 1,680 first-time recipients of HRT, two thirds of initial prescriptions were written by internists. Thirty-eight percent discontinued HRT within 1 year. For the subset whose indication for therapy was ascertained, prevention of chronic disease was associated with a 33% 1-year discontinuation rate. Factors associated with longer duration of therapy included white race (relative risk [RR], 1.63; 95% confidence interval [95% CI], 1.32 to 2.02), younger age (RR, 1.02 per year; 95% CI 1.01 to 1.03), and changing the preparation or dose of estrogen (RR, 5.62; 95% CI, 4.33 to 7.25). The formulation (esterified estrogens 0.625 mg versus conjugated estrogens 0.625 mg) was also associated with greater duration of use; all other estrogens were, as a group, associated with shorter duration of use. Those who received their initial HRT prescription from an internist were more likely to continue therapy than those who received it from a gynecologist.
Conclusions: Despite increased use of HRT, only a minority of women in this population used HRT, and many of those discontinued therapy within 1 year.
Figures




Similar articles
-
Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.Menopause. 1998 Fall;5(3):152-6. Menopause. 1998. PMID: 9774760
-
Hormone replacement therapy and the risk of subarachnoid hemorrhage in postmenopausal women.J Neurosurg. 2016 Jan;124(1):45-50. doi: 10.3171/2014.12.JNS142329. Epub 2015 Jul 10. J Neurosurg. 2016. PMID: 26162033
-
Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women.Ann Vasc Surg. 2012 Apr;26(3):411-8. doi: 10.1016/j.avsg.2011.10.012. Epub 2012 Jan 30. Ann Vasc Surg. 2012. PMID: 22285341
-
Postmenopausal hormone replacement therapy: scientific review.JAMA. 2002 Aug 21;288(7):872-81. doi: 10.1001/jama.288.7.872. JAMA. 2002. PMID: 12186605 Review.
-
Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative.J Manag Care Pharm. 2008 Apr;14(3 Suppl):7-13. doi: 10.18553/jmcp.2008.14.S3-A.7. J Manag Care Pharm. 2008. PMID: 18439061 Free PMC article. Review.
Cited by
-
Time-efficient, high-resistance inspiratory muscle strength training for cardiovascular aging.Exp Gerontol. 2021 Oct 15;154:111515. doi: 10.1016/j.exger.2021.111515. Epub 2021 Aug 10. Exp Gerontol. 2021. PMID: 34389471 Free PMC article. Review.
-
Inspiratory muscle strength training for lowering blood pressure and improving endothelial function in postmenopausal women: comparison with "standard of care" aerobic exercise.Front Physiol. 2022 Aug 29;13:967478. doi: 10.3389/fphys.2022.967478. eCollection 2022. Front Physiol. 2022. PMID: 36105300 Free PMC article.
-
Hormone Replacement Therapy and the Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: a Nationwide Population-Based Study (2009-2018).Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):2019-2029. doi: 10.1007/s00417-023-05976-8. Epub 2023 Jan 21. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36680611
-
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.Osteoporos Int. 2003 Oct;14(10):808-13. doi: 10.1007/s00198-003-1431-2. Epub 2003 Sep 11. Osteoporos Int. 2003. PMID: 14523610
-
Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study.Ann Clin Psychiatry. 2009 Apr-Jun;21(2):70-6. Ann Clin Psychiatry. 2009. PMID: 19439155 Free PMC article. Clinical Trial.
References
-
- Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37. - PubMed
-
- Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–61. - PubMed
-
- Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756–62. - PubMed
-
- Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9–16. - PubMed
-
- Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical